Highly attenuated poxvirus vectors.
Tartaglia
J
J
Virogenetics Corporation, Troy, NY 12180.
Cox
W I
WI
Taylor
J
J
Perkus
M
M
Riviere
M
M
Meignier
B
B
Paoletti
E
E
D016915:AIDS Vaccines; D000818:Animals; D005822:Genetic Vectors; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D016867:Immunocompromised Host; D051379:Mice; D008807:Mice, Inbred BALB C; D011212:Poxviridae / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D012900:Smallpox Vaccine; D014611:Vaccination / Q000009:adverse effects; D014613:Vaccines, Attenuated / Q000633:toxicity; D014614:Vaccines, Synthetic / Q000633:toxicity; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity; D014765:Viral Vaccines / Q000276:immunology / Q000633:toxicity
D016915:AIDS Vaccines; C078788:ALVAC vaccine; C078786:DryVax vaccine; C078787:NYVAC vaccine; D011994:Recombinant Proteins; D012900:Smallpox Vaccine; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines